Summary: Jazz Pharmaceuticals reported record revenues exceeding $1 billion for Q2 2024, driven by strong sales of Xywav in its sleep medicine portfolio, as well as Epidiolex and Rylaze in its seizure and oncology portfolios. The company saw a 13% year-over-year increase in Xywav … [Read more...]
Jazz to Highlight Narcolepsy and IH Research at AAN 2024
Summary: Jazz Prescribed drugs will existing five abstracts at the 76th Once-a-year American Academy of Neurology Conference in Denver that aim on narcolepsy and idiopathic hypersomnia. Essential conclusions include things like a authentic-planet promises evaluation demonstrating … [Read more...]